改善2型糖尿病患者的不良心血管结局:GLP-1RA与SGLT-2i可联合应用吗?

Improve Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus:Can GLP-1RA be Combined with SGLT-2i

心血管疾病是糖尿病患者死亡最常见的原因,预防心血管并发症是糖尿病患者治疗的一个关键目标,现有证据表明,钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂是两类可改善2型糖尿病患者的不良心血管结局的降糖药物,联合应用是否可在预防糖尿病患者心血管并发症上取得更大获益,现就其最新进展进行总结概括。

Cardiovascular disease is the most common cause of death in people with diabetes, the prevention of cardiovascular disease is a key in the treatment of patients with type 2 diabetes mellitus.Existing evidence suggests that sodium-glucose cotransporter-2 inhibitor and glucagon-like peptide-1 receptor agonist are two classes of hypoglycemic agents that can improve adverse cardiovascular outcomes in patients with type 2 diabetes mellitus.Whether combined use can achieve greater benefit in preventing cardiovascular complications in patients with diabetes mellitus.This paper summarizes its latest development.